Drug Index


Mechanism :

Nelarabine, a prodrug of ara-G, is demethylated by adenosine deaminase to ara-G and then converted to ara-GTP. Ara-GTP is incorporated into the DNA of the leukemic blasts, leading to inhibition of DNA synthesis and inducing apoptosis.

Indication :

  • Treatment of relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma following at least 2 chemotherapy regimens.

Contraindications :

Hypersensitivity to nelarabine or any component of the formulation.

Dosing :

650 mg/m²/dose on days 1 through 5; repeat every 21 days.

Adverse Effect :

Anemia, neutropenia, thrombocytopenia, fatigue, headache, peripheral neurologic disorder, hypoesthesia, paresthesia, pain, asthenia, fever, edema, petechiae, cough, dyspnea, pleural effusion, diarrhea, nausea, vomiting, myalgia, seizures, Fatal opportunistic infections, Demyelination and ascending peripheral neuropathies.

Interaction :

Clozapine: Myelosuppressive Agents may enhance the adverse/toxic effect of Clozapine.
Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.
Pentostatin: May diminish the antineoplastic effect of Nelarabine.
Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of live vaccines.

Hepatic Dose :

No dose adjustments are recommended.
03/24/2024 11:51:28 Nelarabine
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0